LUNG-ROLL: Treatment patterns and costs for people with lung cancer in Canada
Official title: LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
Run by AstraZeneca · NCT07143110 · Data updated 2026-11-12
This project looks at past health records to see how lung cancer is treated and what healthcare it uses for adults in Alberta and Ontario.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 130 Years |
| Sex | All |
| Enrollment | 60000 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 2 sites (Calgary, Alberta and 1 other locations) |
| Status | Recruiting |
| Started | August 20, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07143110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) diagnosed with lung cancer on or after January 1, 2018 who were residents of Alberta or Ontario at diagnosis and had at least 12 months of prior health insurance coverage, without other cancers in the five years before 2018 or on the same diagnosis date, are included.
✕Probably not a fit
People who live outside Alberta or Ontario, were diagnosed before 2018, lack sufficient insurance or administrative records, or have concurrent/very recent other cancers are not represented and are unlikely to benefit directly from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
LUNG-ROLL is a retrospective cohort using provincial administrative health data from Alberta and Ontario beginning January 1, 2018 to describe contemporary treatment patterns, incidence and prevalence, patient demographics, clinical outcomes, and healthcare resource use and costs among people with lung cancer. Eligible patients are adults diagnosed with lung cancer who had at least 12 months of health insurance coverage before diagnosis and who were residents of Alberta or Ontario at diagnosis, with several exclusions for prior or concurrent other cancers and incomplete records. The study will use linked administrative datasets to capture treatments, hospital and outpatient care, and cost-related billing records to quantify resource use. Results will be presented as summary statistics and temporal trends to inform clinicians, health system planners, and policymakers about real-world care and cost drivers.
Why it matters
Potential benefit: If successful, the findings could help health systems and clinicians understand real-world treatment patterns and cost drivers to improve resource planning and patient care.
How similar studies have gone: Similar retrospective administrative database studies of lung cancer have been used successfully to describe treatment patterns, outcomes, and costs and to inform policy, though findings vary by region and data completeness.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with lung cancer between January 1, 2018 and end of the Selection Period. * Patient is 18 years of age or older on diagnosis date. * Patient has at least 12 months of health insurance coverage prior to the diagnosis date. Exclusion Criteria: * Diagnosed with any other cancer in the 5-year period prior to January 1, 2018. * Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis. * Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type). * Non-Ontario or non-Alberta resident on diagnosis date.
Where it's running
-
Research Site
Calgary, Alberta, Canada Recruiting -
Research Site
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Telerehabilitation exercise program after lung cancer surgery
A remote rehabilitation program with guided exercises is tested to help adults after lung cancer surgery recover better.
-
Impact of Exercise on Tumor Immunity in NSCLC Patients Receiving Neoadjuvant Chemo-Immunotherapy
A structured exercise program is being tested to see if it boosts immune cells in the tumor for patients with resectable NSCLC undergoing pre-surgery chemo-immunotherapy.
-
Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake
This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.
-
Nitride-based Raman biochip for lung cancer diagnosis and monitoring
A large observational study in Taiwan will test whether a blood-based nitride-based Raman biochip can help diagnose lung cancer and monitor patients over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.